Exagen Inc. (XGN) Q1 2026: Revenue Rises on AVISE Momentum, but the Operating Loss Lingers

In its first quarter 2026 report, Exagen Inc.—traded as XGN—presents another chapter in the diagnostics saga: revenue growth against a backdrop of ongoing operating losses. The filing, dated May 11, 2026, flags unaudited results for the quarter ended March 31, 2026 and highlights the AVISE platform’s continuing role in revenue mix and price discipline.

Snapshot of the quarter

Exagen reports for the three months ended March 31, 2026 with revenue of $17.306 million (thousands, as disclosed in the filing), up from $15.498 million in the prior-year period. The press release emphasizes a record total revenue and a record AVISE CTD average selling price (ASP), underscoring ongoing strength in the core AVISE testing line. The company reiterates that the data are unaudited and presented in thousands, except ASP data, and it situates the date in Carlsbad, California—the usual theater for Exagen’s performance updates.

Financials in focus

The gross margin for the quarter sits at 59.0% (vs. 58.9% in the prior-year period), signaling marginal margin improvement on higher revenue. On the expense side, operating expenses run $13.619 million for the quarter, compared with $12.488 million a year earlier. Net effect: an operating loss of roughly $3.4 million for the quarter, based on the arithmetic of gross profit and operating costs from the reported figures. In other words, Exagen is growing top-line revenue while continuing to burn cash in the classic early-stage diagnostics playbook.

As is common in press-release style quarterly disclosures, the document mentions “Unaudited. In thousands, except ASP data.” The seeding of AVISE CTD ASP as a highlighted metric suggests management sees pricing discipline and product mix as levers for value, even as the bottom line remains in the red for now.

What this means for Exagen and the sector

From a reader’s seat, the narrative is clear: revenue growth is modest but meaningful, and gross margins are maintaining a stable trajectory. The fact that AVISE-related ASP is singled out as recordable implies customers are continuing to transact at higher value points within the AVISE ecosystem, which is a positive sign for long-term pricing power.

In terms of earnings analysis, the filing does not present an EPS figure or a formal earnings-per-share narrative in the extract, so any EPS consensus or earnings surprise assessment must await additional disclosures or analyst models. The absence of explicit EPS numbers in this portion means the market will be parsing the quarter’s performance against expectations once guidance or a more detailed supplemental packet arrives. Investors and analysts typically watch for whether the company can convert revenue momentum into a path toward positive EPS, or at least a clearly defined roadmap to profitability.

Implications for peers and the broader diagnostics space

Exagen’s quarterly footprint reinforces a broader trend in autoimmune diagnostics: specialty panels and platform-based testing can deliver outsized ASPs even as the investment cadence remains steep. For sector peers, the message is twofold. First, maintaining a high-value product mix (like AVISE) appears crucial to sustaining gross margins in a market where volume growth alone may not suffice to reach profitability quickly. Second, transparency around EPS, revenue forecast, and explicit earnings surprises will drive how the stock and its peers are valued in the market during a period of continued investment in sales, marketing, and R&D.

Investors should also watch how the company balances growth investments with cost discipline, a dynamic that often determines whether the sector peers can translate top-line strength into earnings leverage over time. If Exagen can sustain or expand its AVISE-driven revenue while controlling operating expenses, the sector’s valuations may re-rate on the back of a credible profitability pathway rather than just growth chatter.

Forward look and what to monitor

Key items to track going forward include: any provided EPS figures or formal EPS guidance, the company’s revenue forecast updates for the next quarter and full year, and any updates to the EPS consensus from sell-side analysts. The presence of a “record AVISE CTD ASP” suggests pricing and product mix momentum, but the sustainability of this trend remains contingent on market adoption, payer dynamics, and competitive positioning in autoimmune testing.

As always, the sector’s health will hinge on modest gains turning into durable profitability. Management commentary on path to profitability, optionality in product lines beyond AVISE, and the cadence of operating expenses will shape how Exagen and its peers are valued in the near term.

Bottom line

Exagen’s Q1 2026 results show a tangible step forward in revenue and a stable gross margin, but the quarter’s operating loss underscores the ongoing investment phase that many diagnostic players navigate. For the market, the key questions are whether EPS can turn positive in a future quarter, whether the company can sustain a favorable revenue forecast, and how the earnings surprise narrative will unfold as more detailed guidance lands. In the meantime, XGN remains a name reporters and analysts will watch for the trajectory of AVISE adoption and the economics of the CTD testing suite.